Background. Gastrointestinal symptoms (GIS) in people with Parkinson’s disease (PwP) are often underreported and may remain untreated. Constipation is a common nonmotor symptom that can adversely affect health-related quality of life (QoL); however, the impact of other GIS has not been adequately investigated. 

Objectives. To investigate the relationship between QoL and constipation using the Bristol Stool Chart, bowel movement frequency, and a perceived constipation measure; and to explore the relationship between QoL and other GIS in an Australian PD cohort.

Methods. The impact of constipation and other GIS on QoL, as measured using the PDQ-39 scale, was assessed in a cohort of 144 (89 males, 55 females) clinic-attending PwP. Constipation was assessed using the Bristol Stool Chart as well as a composite constipation measure, and the Gastrointestinal Symptom Rating Scale (GSRS) was used to rate other GIS. Covariate corrected linear regression models were utilised to determine significant associations between GIS and QoL scores.

Results. Individual and combined constipation measures were significantly associated with poorer QoL ($p = 0.032$ and $p = 0.002$, respectively). Analysis of GSRS symptom domains showed that in addition to symptoms of gastrointestinal hypomotility, a number of other symptoms such as increased eructation and increased flatus were also associated with poorer QoL. 

Conclusions. The findings point to the importance of GIS as contributors to health-related QoL in PwP. A better understanding of the relationship between GIS and QoL will help facilitate the development of more effective screening and treatment programs to improve symptom management and QoL for PwP.

1. Introduction

Parkinson’s disease (PD) is a complex, progressive neurodegenerative disorder that was originally typified by its characteristic and clinically defining motor symptoms including, tremor, bradykinesia, rigidity, and postural instability. It is now recognised that a plethora of nonmotor symptoms (NMS) also occur and may antedate the characteristic motor symptoms of the disease [1–3]. These NMS include but are not limited to cognitive decline, mood and sleep disturbances, an impaired sense of smell, and a wide range of gastrointestinal symptoms [3, 4]. In fact, research indicates that the NMS of PD may have a greater impact on health-related quality of life than the cardinal motor symptoms [5, 6]. As PD does not have a cure or treatment to slow disease progression, research needs to focus on identifying factors that can be treated to improve patient quality of life.

Health-related quality of life (QoL) is defined as “the patient’s own perception and self-evaluation regarding the effects of an illness and its consequences on his or her life” [7]. In complex, progressive disorders, like Parkinson’s
disease, with a wide range of motor and nonmotor symptoms, QoL is an important factor to consider when managing the disease as each individual will be unique, in terms of the combination of symptoms at any particular time-point in the course of the disease. Although constipation can affect QoL in PwP [6, 8, 9], gastrointestinal symptoms remain as the top underreported [10, 11], and thus, untreated symptoms in PD [5], leading to suboptimal clinical care and poorer QoL [12]. Whereas the adverse effects of other NMS such as cognitive impairment [13, 14] and sleep disturbances [15, 16], on QoL in PD are well-documented, the impact of gastrointestinal symptoms on QoL in PD populations has received relatively little attention in the literature.

Gastrointestinal symptoms (GIS), including constipation and nausea, are reported to be amongst the earliest symptoms to develop in PD, manifesting up to 20 years prior to the clinically defining motor symptoms [17, 18]. It is reported that 60–80% of people with PD (PwP) experience constipation [19], with almost all PwP experiencing GIS at some time throughout their disease course. A positive relationship also exists between inflammatory bowel diseases and the risk of developing PD and has been reported in many populations [20–22]. Additionally, proinflammatory bacterial species in the gut microbiome, which can manifest clinically as GIS, have been shown to be increased in PwP [23–28]. Thus, the link between GIS and PD is well established. As such, a disease-specific Gastrointestinal Dysfunction Scale for PwP has recently been proposed [29]. However, the extent to which GIS specifically impact on QoL in people with PwP remains unclear. Therefore, there is a need to better understand the relationship between constipation and other GIS and QoL in PwP to help facilitate the development of more effective screening and treatment programs and to improve patient quality of life.

The aims of the present study were: (i) to investigate the relationship between QoL and constipation using the Bristol Stool Chart, bowel movement frequency, and a perceived constipation measure; and (ii) to further explore the relationship between QoL and other GIS using the comprehensive Gastrointestinal Symptom Rating Scale (GSRS), in an Australian PD cohort.

2. Materials and Methods

2.1. Ethical Compliance. The study was approved by the Human Research Ethics Committees of The University of Western Australia (RA/4/20/4470) and St. Vincent’s Hospital, Melbourne (LRR137/18). Prior to inclusion in the study, all participants were required to provide written informed consent and were free to withdraw from the study at any time. All work was conducted in accordance with the Declaration of Helsinki (1964).

2.2. Participants. Participants diagnosed with idiopathic PD (n = 144; 89 M/55 F) were recruited from Movement Disorders Clinics at the Perron Institute for Neurological and Translational Science (Perth, WA) and St. Vincent’s Hospital (Melbourne, VIC) and assessed at respective clinics by the same researcher (JK) to mitigate potential bias. All participants were previously examined by a movement disorders neurologist for verification of the diagnosis in accordance with the UK Brain Bank Criteria for idiopathic PD [30], were ambulant, and none were known to have any other neurological disorders.

2.3. Clinical Assessments. Participants were assessed in the “ON” state using the Movement Disorders Society Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) Parts I–IV, with a higher score representing greater disease severity. Nonmotor and motor experiences of daily living were evaluated by MDS-UPDRS parts I and II, respectively. The severity of motor symptoms, and motor complications were evaluated by MDS-UPDRS Parts III and IV, respectively, and overall disease severity was rated using the Hoehn and Yahr scale. PD medications were categorised into six medication classes: levodopa (L-DOPA), dopamine agonists (DA), catechol-O-methyl transferase inhibitors (COMT-I) with levodopa, monoamine oxidase inhibitors (MAO-I), anticholinergics, and amantadine, and reported daily dosages were converted into a levodopa equivalent daily dosage (LEDD), as previously described [31]. Gastrointestinal symptoms were assessed using the Gastrointestinal Symptom Rating Scale (GSRS) as previously described [32]. The GSRS is a 15-question patient-compiled scale in which gastrointestinal symptoms during the preceding 3 months are evaluated individually on a 0–4 scale.

2.4. Constipation Assessments. This study used three individual measures and one combined measure of constipation. The first individual measure, the Bristol Stool Chart, is an extensively used stool form measurement tool with an ordinal scale of stool types ranging from Type 1 (hardest) to Type 7 (softest). Types 1 and 2 are considered abnormally hard (indicative of constipation), Types 3, 4, and 5 are considered normal, and Types 6 and 7 are considered abnormally loose. The second individual measure recorded was the frequency of bowel movements per day. The third individual measure was a perceived constipation question, where participants were asked whether they considered themselves to suffer from constipation or not and hereon will be referred to as “self-reported constipation.” As constipation refers to hard to pass and/or infrequently passed stool [33], all three individual constipation measures were then coded together, with any individual fitting the criteria for constipation in two or more of the individual constipation measures being coded as “constipated” in the combined measure of constipation.

2.5. Quality of Life Assessment. Participants completed a self-report 39-question Parkinson’s disease quality of life (PDQ-39) questionnaire to evaluate Parkinson’s disease specific health-related quality of life over the previous month. The PDQ-39 is one of the most frequently adopted and highly recommended assessments for QoL in individuals with PD [25]. Each question was answered on a 5-stage scale, ranging
from 0 = never, 1 = occasionally, 2 = sometimes, 3 = often, 4 = always/or cannot do at all. This questionnaire measures the following eight domains of quality of life: mobility, activities of daily living, emotional wellbeing, stigma, social support, cognition, communication, and bodily discomfort. Higher scores represented a lower quality of life.

2.6. Statistical Analyses. Statistical analyses were run on IBM SPSS (v. 28.0.1.0, IBM Corporation). Quantitative data were expressed as mean (SD), and categorical variables were expressed as n (%). All variables were assessed for normality using the Kolmogorov–Smirnov and returned significant values (p < 0.001). Differences in mean PDQ-39 total score, when grouped according to constipation and stool measures, were determined using the Mann–Whitney U tests, when grouped into binary variables, and Generalised Linear Models (GLMs), when kept as continuous variables, to correct for covariates. To further investigate associations between GSRS scores and the PDQ-39 total score, naïve and corrected GLMs were utilized. To assess for multicollinearity, the variance inflation factor (VIF) was calculated for all independent variables. For all reported models, VIF values were less than 2. A nominal p value of <0.05 was regarded as being statistically significant.

3. Results

3.1. Cohort Demographic and Clinical Data. Demographic and clinical assessment details for the PwP cohort are presented in Table 1. The average age of participants was 65.6 (SD = 9.19), and just over half were males (61.8%). PwP had a mean MDS-UPDRS III motor score of 21.81 (SD = 14.16) and had an average Hoehn and Yahr score of 2.03 (SD = 0.77). Of the participants, the majority were taking antiparkinsonian medications (95.9%), with an average LEDD of 816.44 (SD = 629.69), and the most commonly taken medication was levodopa (84.7%).

3.2. Poorer Quality of Life Correlates with NMS and Constipation. Within the cohort, nonmotor symptoms of PD, measured by the UPDRS Part I, were significantly correlated with a poorer quality of life, as determined by the PDQ-39 score (r = 0.616, p < 0.001; Figure 1(a)). To determine the effect of constipation on QoL, the cohort was grouped based on multiple measures of constipation (Figure 1). When grouped by the frequency of bowel movements per day, with less than once a day grouped into the “constipated” group, and once or more into the “not constipated” group, individuals who passed less than one bowel movement a day trended towards a lower quality of life (p = 0.223; Figure 1(b)). When grouped by the Bristol Stool Chart rating of their bowel movements, individuals who rated their bowel movements as Types 1 and 2 were grouped into the “constipated” group, and those who rated Types 3–7 into the “not constipated” group. Participants who were grouped into the “constipated” group also trended towards a poorer quality of life than those grouped into the “not constipated” group (p = 0.238; Figure 1(c)).

Participants were also asked whether they considered themselves to be constipated or not constipated in the self-reported constipation question, and those that considered themselves to be constipated had a significantly poorer quality of life than those who did not consider themselves constipated (p = 0.023; Figure 1(d)). Lastly, when all measures of constipation were combined into one variable, those that were classed as “constipated” had a significantly poorer quality of life than those who were not classed as constipated (p = 0.002; Figure 1(e)).

Univariate correlations showed significant associations between LEDD (r = 0.347; p < 0.001) and disease duration (r = 0.468, p < 0.001) with quality of life. As such, these factors were incorporated as covariates into GLM models looking at the above constipation measures (Table 2). GLMs revealed significant associations between the “self-reported constipation question,” and poorer quality of life in both naïve (p = 0.005) and covariate corrected models (p = 0.024). When all three constipation questions were combined, results also demonstrated a significant association with poorer quality of life in both naïve (p < 0.001) and corrected models (p = 0.006).

| Table 1: Demographic and clinical characteristics of the cohort. |   |
|---------------------------------------------------------------|---|
| Measures                                                      | PD (n = 144) |
| Age (years)                                                   | Mean (SD) or n (%) |
| Gender                                                       | Male: 65.6 (9.19) |
| Age of onset                                                  | 89 (61.8%) |
| Disease duration                                              | 56.96 (10.56) |
| LEDD (mg)                                                    | 8.61 (6.02) |
| PD medications                                               | L-DOPA: 816.44 (629.69) |
|                                                             | DA: 122 (84.7%) |
|                                                             | COMT-I: 67 (46.5%) |
|                                                             | MAO-I: 37 (25.7%) |
|                                                             | Amantadine: 38 (26.4%) |
|                                                             | Anticholinergics: 21 (14.6%) |
|                                                             | Unmedicated: 0 (0%) |
| MDS-UPDRS                                                    | Part I: 10.79 (6.63) |
|                                                             | Part III: 21.81 (14.16) |
|                                                             | 2.03 (0.77%) |
|                                                             | Stage 1: 32 (22.2%) |
|                                                             | Stage 2: 83 (57.6%) |
|                                                             | Stage 3: 21 (14.6%) |
|                                                             | Stage 4: 8 (5.6%) |
|                                                             | Stage 5: 0 (0%) |
|                                                             | 41 (28.1%) |
| History of GI illness                                         | IBS: 10 (6.9%) |
|                                                             | IBD: 3 (2.05%) |
| Other GI symptoms                                             | 19 (13.0%) |

*8 other GI symptoms refers to other reported GI symptoms not organised into the 4 categories, such as diverticulitis, constipation, appendicitis, easily upset/sensitive stomach, recurring gastro episodes, strangulated bowel, incontinence. PD: Parkinson’s disease. SD: standard deviation. LEDD: levodopa equivalent daily dosage. L-DOPA: levodopa. DA: dopamine agonists. COMT-I: catechol-O-methyltransferase inhibitor. MAO-I: monoamine oxidase inhibitor. MDS-UPDRS: movement disorders society unified Parkinson’s disease rating scale. IBS: irritable bowel syndrome. IBD: inflammatory bowel disease. PU: peptic ulcer. GI: gastrointestinal.
3.3. Poorer Quality of Life is Associated with GSRS Symptoms and Domains. Although the total gastrointestinal symptom score was not significantly associated with poorer quality of life, linear regression models showed that there was an association with specific gastrointestinal symptoms and symptom domains (Table 3). In the naïve models, increased eructation ($p = 0.027$), decreased passage of stools ($p = 0.026$), feeling of incomplete evacuation ($p = 0.002$), and the hypoactive GI symptom domain ($p = 0.001$) were all significantly associated with poorer QoL; while in the corrected models, increased flatus ($p = 0.011$), and increased eructation ($p = 0.047$) were also both significantly associated with poorer QoL.
4. Discussion

Previous QoL studies in Parkinson’s disease have focused largely on the impact of NMS, such as sleep disturbances and cognitive impairment [13–16], rather than the range of gastrointestinal and other symptoms that PwP may experience. In the current study, we investigated various measures of constipation and their relationship with QoL in an Australian cohort of PwP and found that suffering from constipation was significantly associated with a reduced QoL as measured with the PDQ-39 instrument. We went on to further explore the relationship between other gastrointestinal symptoms and QoL using the comprehensive Gastrointestinal Symptom Rating Scale (GSRS), which has previously been used to evaluate the frequency and severity of gastrointestinal symptoms in assorted clinical settings [32, 34–45], but not in a QoL study in PwP. Our findings confirmed that, in addition to constipation and other symptoms of gastrointestinal hypomotility, a number of other gastrointestinal symptoms that are not included in current clinical assessment protocols also had a negative impact on QoL.

The UPDRS Part I is a measure of nonmotor activities of daily living and gives a broad overview of nonmotor symptoms experienced by the individual. As NMS are so prevalent in PwP, it is not surprising that we found a significant correlation between increasing difficulties with nonmotor symptoms and a poorer quality of life. These results confirmed similarly reported associations in various PwP populations where NMS were found to be a significant burden to QoL [1, 5, 9, 11, 13–16, 46, 47]. However, as the UPDRS Part I is very broad, it is also superficial in terms of measuring the burden of gastrointestinal symptoms, with only a single question relating to constipation, thereby overlooking the plethora of other gastrointestinal symptoms experienced by PwP. To this end, we therefore investigated the impact of constipation on the QoL of PwP using multiple measures.

The three individual constipation measures utilised in this study were, frequency of defecation, consistency of stool passed using the Bristol Stool Chart, and a question gauging whether participants considered themselves to be constipated or not (referred to as “self-reported constipation”). All four measures revealed a trend towards constipation being associated with a poorer quality of life, with only the GSRS question and combined measures reaching statistical significance, even after adjusting for LEDD and disease duration. Although constipation is generally accepted as being one of the earliest prodromal symptoms in PwP [48], it is still considered a “taboo” topic by many individuals [11], and is thus less likely to be reported, and therefore, to remain untreated [5], and to significantly impact on QoL [12]. This is consistent with the findings of a study that reported a discrepancy of 76% between objectives versus subjectively reported constipation in a population of PwP [10].
In our study, we found that individual gastrointestinal symptoms, other than constipation also contributed significantly to a poorer QoL. These included increased eruction, decreased passage of stools, a feeling of incomplete evacuation, and increased flatus. The impact of these symptoms is compounded further by being more prevalent in PwP [32], contributing to an added burden on QoL that is disease specific. Thus, these results shed light on a group of symptoms that are being overlooked in relation to their contribution to QoL and that may be amenable to treatment in order to improve the QoL of PwP.

Parkinson’s disease has been associated with a high burden of gastrointestinal dysfunction and comorbidities, in particular constipation and reduced colonic transit time, affecting up to 80% of all PwP [48, 49]. Furthermore, the severity of these GIS has been found to increase with the progression of the disease [50, 51]. Constipation, delayed gastric emptying, and changes in stool’s consistency have also been linked with more rapid and severe motor and cognitive decline in PD [28, 32, 52]. In addition, an association between PD and inflammatory bowel diseases (e.g., Crohn’s disease, ulcerative colitis, and irritable bowel syndrome) has been reported in assorted populations [22, 53]. Together, it is thought that, as a consequence of disease pathology, the function of the enteric nervous system can become progressively impaired in PwP [54–56]. This can result in impaired intestinal mobility and further exacerbation of gastrointestinal dysfunction as the disease progresses [57]. Thus, coinciding with evidence that gastrointestinal NMS can have considerable effects on the quality of life of PwP as well as placing a heavy burden on their carers [58].

5. Conclusions

In the present study, we have carried out an in-depth analysis of the frequency and impact of GIS on health-related QoL in a cohort of clinic-attending PwP. In addition to confirming the significant role of constipation and other symptoms of gastrointestinal hypomotility, our findings highlight a number of other GIS that are not commonly reported, that may also have significant effects on patient QoL. The results are consistent with the notion that current standard PD assessments do not comprehensively cover the full range of GIS [5, 32] and that individuals with PD are less likely to report GIS when not directly probed [11], meaning these symptoms are often overlooked, and may remain untreated, and contribute to poorer QoL. Thus, early identification and treatment of GIS in PwP has the potential to result in a significant improvement in QoL. Furthermore, it could help facilitate the development of more effective therapies to improve symptom management, and provide potential for developing a new diagnostic framework for recognising GIS in patients with early motor manifestations, or in the prodromal stages of the disease.

Data Availability

The data are available upon reasonable request from the corresponding author.

Conflicts of Interest

The authors declare that there are no conflicts of interest relevant to this work.

Acknowledgments

The authors would like to thank Ms. Sue Walters and the Perron Clinic Team for providing assessment training and unmatched logistical support, as well as Professor Soumya Ghosh for providing access to participants through the Perron Movement Disorders Clinic and would also like to thank Professor Malcolm Horne and Ms. Sarah Osborne for making it possible to recruit participants through the St Vincent’s Hospital Movement Disorders Clinic and for their generous support. This study was funded by the Parkinson’s WA Zriniski Research Grant 2019, Perron Institute of Neurological and Translational Science, and The University of Notre Dame Australia. This research was carried out while JEK was in receipt of a Perron Prestige Scholarship and a Research Training Program Scholarship at The University of Western Australia.

References

[1] C. Pont-Sunyer, A. Hotter, C. Gaig et al., “The onset of nonmotor symptoms in Parkinson’s disease (the onset pd study),” Movement Disorders, vol. 30, no. 2, pp. 229–237, 2015.

[2] D. M. Swallow, M. A. Lawton, K. A. Grosset et al., “Variation in recent onset Parkinson’s disease: implications for prodromal detection,” Journal of Parkinson’s Disease, vol. 6, no. 2, pp. 289–300, 2016.

[3] T. K. Khoo, A. J. Yarnall, G. W. Duncan et al., “The spectrum of nonmotor symptoms in early Parkinson disease,” Neurology, vol. 80, no. 3, pp. 276–281, 2013.

[4] M. Lubomski, R. L. Davis, and C. M. Sue, “Gastrointestinal dysfunction in Parkinson’s disease,” Journal of Neurology, vol. 267, no. 5, pp. 1377–1388, 2020.

[5] D. A. Gallagher, A. J. Lees, and A. Schrag, “What are the most important nonmotor symptoms in patients with Parkinson’s disease and are we missing them?” Movement Disorders, vol. 25, no. 15, pp. 2493–2500, 2010.

[6] M. A. Bock, E. G. Brown, L. Zhang, and C. Tanner, “Association of motor and nonmotor symptoms with health-related quality of life in a large online cohort of people with Parkinson disease,” Neurology, vol. 98, no. 22, pp. e2194–e2203, 2022.

[7] T. Who, “The world health organization quality of life assessment (whoqol): position paper from the world health organization,” Social Science & Medicine, vol. 41, pp. 1403–1409, 1995.

[8] S. Rahman, H. J. Griffin, N. P. Quinn, and M. Jahanshahi, “Quality of life in Parkinson’s disease: the relative importance of the symptoms,” Movement Disorders, vol. 23, no. 10, pp. 1428–1434, 2008.

[9] N. Malek, M. A. Lawton, K. A. Grosset et al., “Autonomic dysfunction in early Parkinson’s disease: results from the United Kingdom tracking Parkinson’s study,” Mov Disord Clin Pract, vol. 4, pp. 509–516, 2017.

[10] K. Knudsen, T. D. Fedorova, A. C. Bekker et al., “Objective colonic dysfunction is far more prevalent than subjective constipation in Parkinson’s disease: a colon transit and
Parkinson's Disease

volume study,” Journal of Parkinson’s Disease, vol. 7, no. 2, pp. 359–367, 2017.

[11] J. Kaye, H. Gage, A. Kimber, L. Storey, and P. Trend, “Excess burden of constipation in Parkinson’s disease: a pilot study,” Movement Disorders, vol. 21, no. 8, pp. 1270–1273, 2006.

[12] A. Sauerbier and K. R. Chaudhuri, “Non-motor symptoms: the core of multi-morbid Parkinson’s disease,” British Journal of Hospital Medicine, vol. 75, no. 1, pp. 18–24, 2014.

[13] Y. He, Y. Tian, H. Han et al., “The path linking disease severity and cognitive function with quality of life in Parkinson’s disease: the mediating effect of activities of daily living and depression,” Health and Quality of Life Outcomes, vol. 19, no. 1, p. 92, 2021.

[14] A. Schonenberg, H. M. Zipprich, U. Teschner, J. Grosskreutz, O. W. Witte, and T. Prell, “Impact of subthreshold depression on health-related quality of life in patients with Parkinson’s disease based on cognitive status,” Health and Quality of Life Outcomes, vol. 19, no. 1, p. 107, 2021.

[15] C. Liguori, V. O. N. Franco, R. Cerro et al., “Sleep problems affect quality of life in Parkinson’s disease along disease progression,” Sleep Medicine, vol. 81, pp. 307–311, 2021.

[16] D. Santos-Garcia, E. S. Castro, T. de Deus Fonticoba et al., “Sleep problems are related to a worse quality of life and a greater non-motor symptoms burden in Parkinson’s disease,” Journal of Geriatric Psychiatry and Neurology, vol. 34, no. 6, pp. 642–658, 2021.

[17] K. L. Adams-Carr, J. P. Bestwick, S. Shribman, A. Lees, A. Schrag, and A. J. Noyce, “Constipation preceding Parkinson’s disease: a systematic review and meta-analysis,” Journal of Neurology Neurosurgery and Psychiatry, vol. 87, no. 7, pp. 710–716, 2016.

[18] M. G. Cersosimo, G. B. Raina, C. Pecci et al., “Gastrointestinal manifestations in Parkinson’s disease: prevalence and occurrence before motor symptoms,” Journal of Neurology, vol. 260, no. 5, pp. 1332–1338, 2013.

[19] A. T. Nair, V. Ramachandran, N. M. Joghee, S. Antony, and G. Ramalingam, “Gut microbiota dysfunction as reliable non-invasive early diagnostic biomarkers in the pathophysiology of Parkinson’s disease: a critical review,” J Neurogastroenterol Motil, vol. 24, no. 1, pp. 30–42, 2018.

[20] S. W. Lai, Y. H. Kuo, and K. F. Liao, “Increased risk of Parkinson disease in inflammatory bowel disease patients,” Inflammatory Bowel Diseases, vol. 25, no. 10, pp. e125–e126, 2019.

[21] H. S. Lee, E. Lobbestael, S. Vermeire, J. Sabino, and I. Ceynen, “Inflammatory bowel disease and Parkinson’s disease: common pathophysiological links,” Gut, vol. 70, no. 2, pp. 408–417, 2021.

[22] M. Villumsen, S. Aznar, B. Pakkenberg, T. Jess, and T. Brudek, “Inflammatory bowel disease increases the risk of Parkinson’s disease: a Danish nationwide cohort study 1977-2014,” Gut, vol. 68, no. 1, pp. 18–24, 2019.

[23] F. Hopfner, A. Kunstner, S. H. Muller et al., “Gut microbiota in Parkinson disease in a northern German cohort,” Brain Research, vol. 1667, pp. 41–45, 2017.

[24] J. E. Kenna, E. G. Chua, M. Bakeberg et al., “Changes in the gut microbiome and predicted functional metabolic effects in an Australian Parkinson’s disease cohort,” Frontiers in Neuroscience, vol. 15, p. 41, Article ID 756951, 2021.

[25] V. A. Petrov, I. V. Saltykova, I. A. Zhukova et al., “Analysis of gut microbiota in patients with Parkinson’s disease,” Bulletin of Experimental Biology and Medicine, vol. 162, no. 6, pp. 734–737, 2017.

[26] D. Pietrucci, R. Cerroni, V. Unida et al., “Dysbiosis of gut microbiota in a selected population of Parkinson’s patients,” Parkinsonism & Related Disorders, vol. 65, pp. 124–130, 2019.

[27] Y. Qian, X. Yang, S. Xu et al., “Alteration of the fecal microbiota in Chinese patients with Parkinson’s disease,” Brain, Behavior, and Immunity, vol. 70, pp. 194–202, 2018.

[28] M. M. Unger, J. Spiegel, K. U. Dillmann et al., “Short chain fatty acids and gut microbiota differ between patients with Parkinson’s disease and age-matched controls,” Parkinsonism & Related Disorders, vol. 32, pp. 66–72, 2016.

[29] M. Camacho, J. C. Greenland, and C. H. Williams Gray, “The gastrointestinal dysfunction scale for Parkinson’s disease,” Movement Disorders, vol. 36, no. 10, pp. 2358–2366, 2021.

[30] A. J. Hughes, S. E. Daniel, L. Killford, and A. J. Lees, “Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases,” Journal of Neurology, Neurosurgery & Psychiatry, vol. 55, no. 3, pp. 181–184, 1992.

[31] C. L. Tomlinson, R. Stowe, S. Patel, C. Rick, R. Gray, and C. E. Clarke, “Systematic review of levodopa dose equivalency reporting in Parkinson’s disease,” Movement Disorders, vol. 25, no. 15, pp. 2649–2653, 2010.

[32] J. E. Kenna, M. C. Bakeberg, A. M. Gorecki et al., “Characterization of gastrointestinal symptom type and severity in Parkinson’s disease: a case-control study in an australian cohort,” Mov Disord Clin Pract, vol. 8, no. 2, pp. 245–253, 2021.

[33] E. Jani Bmarsicano, “Constipation: evaluation and management,” Missouri Medicine, vol. 115, pp. 236–240, 2018.

[34] E. Dimenas, G. Carlsson, H. Glise, B. Israelsson, and I. Wiklund, “Relevance of norm values as part of the documentation of quality of life instruments for use in upper gastrointestinal disease,” Scandinavian Journal of Gastroenterology, vol. 31, no. 221, pp. 8–13, 1996.

[35] P. Karling, M. Maripuu, M. Wikgren, R. Adolfsson, and K. F. Norrback, “Association between gastrointestinal symptoms and affectivity in patients with bipolar disorder,” World Journal of Gastroenterology, vol. 22, no. 38, pp. 8540–8548, 2016.

[36] D. Khanna, V. Nagaraja, H. Gladue, W. Chey, M. Pimentel, and T. Frech, “Measuring response in the gastrointestinal tract in systemic sclerosis,” Current Opinion in Rheumatology, vol. 25, no. 6, pp. 700–706, 2013.

[37] K. R. Kulich, C. Calabrese, F. Pacini, S. Vigneri, J. Carlsson, and I. K. Wiklund, “Psychometric validation of the Italian translation of the gastrointestinal symptom-rating scale and quality of life in reflux and dyspepsia questionnaire in patients with gastro-oesophageal reflux disease,” Clinical Drug Investigation, vol. 24, no. 4, pp. 205–215, 2004.

[38] K. R. Kulich, A. Madisch, F. Pacini et al., “Reliability and validity of the gastrointestinal symptom rating scale (gsrs) and quality of life in reflux and dyspepsia (qolrad) questionnaire in dyspepsia: a six-country study,” Health and Quality of Life Outcomes, vol. 6, no. 1, p. 12, 2008.

[39] B. Ljotsson, M. Jones, N. J. Talley, L. Kjellstrom, L. Agreus, and A. Andreasson, “Discriminant and convergent validity of the gss-ibs symptom severity measure for irritable bowel syndrome a population study,” United European Gastroenterol, vol. 8, no. 3, pp. 284–292, 2020.

[40] D. A. Revicki, M. Wood, I. Wiklund, and J. Crawley, “Reliability and validity of the gastrointestinal symptom rating scale in patients with gastroesophageal reflux disease,” Quality of Life Research An International Journal of Quality of Life
Aspects of Treatment Care and Rehabilitation, vol. 7, no. 1, pp. 75–83, 1998.

[41] G. S. Souza, F. A. H. Sardá, E. B. Giuntini, I. Gumbrevicius, M. B. Morais, and E. Wd Menezes, “Translation and validation of the brazilian Portuguese version of the gastrointestinal symptom rating scale (gsrs) questionnaire,” Arquivos de Gastroenterologia, vol. 53, no. 3, pp. 146–151, 2016.

[42] J. Svedlund, I. Sjdin, and G. Dotevall, “Gsrs--a clinical rating scale for gastrointestinal symptoms in patients with irritable bowel syndrome and peptic ulcer disease,” Digestive Diseases and Sciences, vol. 33, no. 2, pp. 129–134, 1988.

[43] S. B. Bayer, C. M. Frampton, R. B. Gearry, and G. Barbara, “Habitual green kiwifruit consumption is associated with a reduction in upper gastrointestinal symptoms - a systematic scoping review,” Advances in Nutrition, vol. 13, no. 3, pp. 846–856, 2022.

[44] H. M. LoTurco, E. M. Carter, D. E. McInerney, and C. L. Raggio, “Patient-reported prevalence of gastrointestinal issues in the adult skeletal dysplasia population with a concentration on osteogenesis imperfecta,” American Journal of Medical Genetics, Part A, vol. 188, no. 5, pp. 1435–1442, 2022.

[45] C. Yi, X. Wang, H. Ye, J. Lin, and X. Yang, “Patient-reported gastrointestinal symptoms in patients with peritoneal dialysis: the prevalence, influence factors and association with quality of life,” BMC Nephrology, vol. 23, no. 1, p. 99, 2022.

[46] G. D. Kuhlman, J. L. Flananigan, S. A. Sperling, and M. J. Barrett, “Predictors of health-related quality of life in Parkinson’s disease,” Parkinsonism & Related Disorders, vol. 65, pp. 86–90, 2019.

[47] W. M. Liu, R. J. Lin, R. L. Yu, C. H. Tai, C. H. Lin, and R. M. Wu, “The impact of nonmotor symptoms on quality of life in patients with Parkinson’s disease in taiwan,” Neuropsychiatric Disease and Treatment, vol. 11, pp. 2865–2873, 2015.

[48] R. B. Postuma, D. Aarsland, P. Barone et al., “Identifying prodromal Parkinson’s disease: pre-motor disorders in Parkinson’s disease,” Movement Disorders, vol. 27, no. 5, pp. 617–626, 2012.

[49] A. Fasano, N. P. Visanji, L. W. C. Liu, A. E. Lang, and R. F. Pfeiffer, “Gastrointestinal dysfunction in Parkinson’s disease,” The Lancet Neurology, vol. 14, no. 6, pp. 625–639, 2015.

[50] S. Y. Liu, P. Chan, and A. J. Stoessl, “The underlying mechanism of prodromal pd: insights from the parasympathetic nervous system and the olfactory system,” Translational Neurodegeneration, vol. 6, no. 1, p. 4, 2017.

[51] Q. J. Yu, S. Y. Yu, L. J. Zuo et al., “Parkinson disease with constipation: clinical features and relevant factors,” Scientific Reports, vol. 8, no. 1, p. 567, 2018.

[52] M. Camacho, A. D. Macleod, J. Maple-Grodem et al., “Early constipation predicts faster dementia onset in Parkinson’s disease,” NPJ Parkinsons Dis, vol. 7, no. 1, p. 45, 2021.

[53] S. W. Lai, K. F. Liao, C. L. Lin, and F. C. Sung, “Irritable bowel syndrome correlates with increased risk of Parkinson’s disease in taiwan,” European Journal of Epidemiology, vol. 29, no. 1, pp. 57–62, 2014.

[54] F. Baldini, J. Hertel, E. Sandt et al., “Parkinson’s disease-associated alterations of the gut microbiome predict disease-relevant changes in metabolic functions,” BMC Biology, vol. 18, no. 1, p. 62, 2020.

[55] C. Challis, A. Hori, T. R. Sampson et al., “Gut-seeded alpha-synuclein fibrils promote gut dysfunction and brain pathology specifically in aged mice,” Nature Neuroscience, vol. 23, no. 3, pp. 327–336, 2020.

[56] U. Raval, J. M. Harary, E. Zeng, and G. M. Pasinetti, “The dichotomous role of the gut microbiome in exacerbating and ameliorating neurodegenerative disorders,” Expert Review of Neurotherapeutics, vol. 20, no. 7, pp. 673–686, 2020.

[57] A. Mulak, “Brain-gut-microbiota axis in Parkinson’s disease,” World Journal of Gastroenterology, vol. 21, no. 37, pp. 10609–10620, 2015.

[58] M. S. Cirstea, A. C. Yu, E. Golz et al., “Microbiota composition and metabolism are associated with gut function in Parkinson’s disease,” Movement Disorders, vol. 35, no. 7, pp. 1208–1217, 2020.